1,721,109 research outputs found
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence
Full text linkPurpose:
This is a head-to-head comparison between Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA-11) and18F-Fluciclovine Positron Emission Tomography/Computed Tomography (PET/CT) in a series of 10 patients with prostate cancer (PCa) recurrence.Methods:288 patients with PCa recurrence were enrolled in a prospective study of68Ga-PSMA-11 PET/CT imaging for recurrent disease localization (NCT02940262). We retrospectively identified 10 patients who underwent clinical indicated18F-Fluciclovine PET/CT prior enrollment.Results:The median time between both scans was 2.3 months (range 0.2-4.2). The median PSA value was 1.0 ng/ml (mean 4.7 ng/ml; range 0.13-18.1) and 1.1 ng/ml (mean 6.2 ng/ml; range 0.24-31.3) at the time of18F-Fluciclovine and68Ga-PSMA-11 PET/CT, respectively. 5/10 patients (50%) were negative on18F-Fluciclovine PET/CT but showed positive results on68Ga-PSMA-11 PET/CT. 2/10 patients (20%) had both positive18F-Fluciclovine and68Ga-PSMA-11 PET/CT but68Ga-PSMA-11 PET/CT showed additional lymph nodes (LN) metastasis. 3/10 patients (30%) had both negative18F-Fluciclovine and68Ga-PSMA-11 PET/CT.Conclusion:This case series suggests superior detection rate of68Ga-PSMA-11 PET/CT than18F-Fluciclovine PET/CT in recurrent PCa. Prospective trials designed to directly compare68Ga-PSMA-11 and18F-Fluciclovine PET/CT should be initiated
Recommended from our members
Non-oncologic incidental uptake on FAPI PET/CT imaging.
Full text linkFibroblast-activation protein (FAP) is a serine protease classified in the dipeptidyl peptidase 4 (DPP4) family. FAP is predominantly expressed in activated fibroblasts such as the cancer-associated fibroblasts (CAFs). FAP expression in CAFs is associated with tumor progression and poor prognosis in solid cancers. Recently, radiolabeled FAP inhibitors (FAPI) has been developed, which enables positron emission tomography (PET) imaging of FAP. FAPI PET/CT can provide a higher tumor-to-background ratio (TBR) than 18F-fludeoxyglucose PET/CT in various cancers, and thus has attracted substantial attention. As studies on FAPI PET grow in number and size, incidental findings related to non-oncologic conditions have been increasingly reported. FAPI PET uptake has been reported in various conditions such as benign tumors, fibrotic, granulomatosis, scarring/wound, degenerative diseases, and inflammatory diseases.The knowledge of physiological and non-oncologic causes of FAPI uptake is indispensable for accurate FAPI PET/CT interpretation and can help appropriate management of incidental findings on FAPI PET/CT in patients referred for cancer staging indications. In this review article, we describe for each organ system (Brain, Oral mucosa, Salivary Glands, Thyroid, Lung, Myocardium, Breast, Esophagus, Stomach, Intestine, Liver, Gallbladder, Pancreas, Spleen, Kidney, , Uterus, Bone marrow, Joints, Muscle, Vessels, Lymph nodes), the patterns of physiological FAPI uptake and the main causes of non-oncological uptake reported from the literature with FAPI-02, FAPI-04 and FAPI-46. We also illustrate some examples from our institutional database at UCLA
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Recherche Clinique et Translationelle en Radiotheranostique: Habilitation à diriger des recherches (HDR)
No full textRadiotheranostics can be defined as the combined use of a radiopharmaceutical imaging agent (radiotracer) and aradiopharmaceutical therapeutic agent having the same molecular target. Targeted imaging enables the estimationof the individualized biodistribution of the radiopharmaceutical drug for each patient. Following the successfulclinical translation and approvals in the United States and in Europe of radiopharmaceutical therapies targeting SSTR(Lu177-DOTATATE) for neuroendocrine tumors and more importantly PSMA (Lu177-PSMA-617) for metastaticprostate cancer, the radiopharmaceutical market is booming. Taking advantage of the rise of radiotheranostics, I hadthe opportunity to lead as principal investigator numerous clinical and translational research studies at theUniversity of California, Los Angeles (UCLA) (from phase 0 to phase 3) using targeted radionuclide imaging and/ortherapy.This manuscript of Accreditation to Supervise Research (Habilitation à Diriger des Recherches (HDR)) aims atpresenting my scientific contributions since joining UCLA in 2016 with a focus on selected publications in which Iserved as supervisor. For this manuscript, these were arbitrarily grouped in 3 research topics: (1) Clinical Translationof FAP-PET imaging; (2) Randomized Trials of PSMA PET imaging trials powered for clinical outcome; (3) ExploringBeyond the approved use of PSMA theranostics.There are many research perspectives for improving the use of FAP-targeted and PSMA-targeted radiotheranostics.Multiple other molecular targets (CA-IX, SSTR, GRPR, GPC3) and applications (dosimetry, artificial intelligence) arebeing studied and numerous clinical trials are currently being conducted (phase 0 to phase 3). There are massivefinancial investments from major pharmaceutical groups into the radiopharmaceutical market. Leveraging thisindustry dynamism and flow of investments can enable the nuclear medicine community to offer cancer patientsand their doctors a maximum of innovative radiopharmaceutical techniques.La radiothéranostique peut être défini comme l’utilisation combinée d’un agent radiopharmaceutique d’imagerie(radiotraceur) et d’un agent radiopharmaceutique thérapeutique (radiothérapie interne vectorisée) ayant la même ciblemoléculaire. L’imagerie ciblée permet d’estimer la biodistribution individualisée du traitement radiopharmaceutique pourchaque patient. Suite au succès de la translation clinique et des autorisations aux Etats-Unis et en Europe des thérapiesradiopharmaceutiques ciblant le SSTR (Lu177-DOTATATE) pour les tumeurs neuroendocrines et le PSMA (Lu177-PSMA-617)pour le cancer de la prostate métastatique, le marché des radiopharmaceutiques est en plein essor. Profitant de l’essor dela radiothéranostique, j’ai eu l’occasion de diriger en tant qu’investigateur principal de nombreuses études de rechercheclinique et translationnelle à l’Université de Californie à Los Angeles (UCLA) (de la phase 0 à la phase 3) en utilisantl’imagerie et/ou la thérapie aux radionucléides.Ce manuscrit de l’Habilitation à Diriger des Recherches (HDR)) vise à présenter mes contributions scientifiques depuis monarrivée à UCLA en 2016 a travers une sélection de publications dont j’ai été le superviseur. Pour ce manuscrit, ceux-ci ontété arbitrairement regroupés en 3 sujets de recherche : (1) Translation clinique de l’imagerie TEP ciblant FAP; (2) Essaiscliniques randomisés d’imagerie TEP ciblant le PSMA; (3) Explorer au-delà de l’utilisation approuvée des radiothéranostiqueciblant le PSMA.Il existe de nombreuses perspectives de recherche pour améliorer l’utilisation des radiothéranostiques ciblant FAP et PSMA.De multiples autres cibles moléculaires (CA-IX, SSTR, GRPR, GPC3) et applications (dosimétrie, intelligence artificielle) sont àl’étude et de nombreux essais cliniques sont actuellement menés (phase 0 à phase 3). Les grands groupes pharmaceutiquesinvestissent massivement dans le marché des radiopharmaceutiques. L’exploitation de ce dynamisme de l’industrie et de ceflux d’investissements peut permettre à la communauté de la médecine nucléaire d’offrir aux patients atteints de cancer età leurs médecins un maximum de techniques radiopharmaceutiques innovantes
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
No full texthttp://dx.doi.org/10.13039/501100005609 Turun Yliopistohttp://dx.doi.org/10.13039/501100011797 Turun Yliopistollinen Keskussairaal
- …
